{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:43:38Z","timestamp":1792640618393,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jfma.2022.03.017","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T17:10:05Z","timestamp":1649351405000},"page":"1371-1383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint inhibitors for hepatocellular carcinoma \u2013 A game changer in treatment landscape"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-4426","authenticated-orcid":false,"given":"Tsung-Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Chun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Lii","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jfma.2022.03.017_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.jfma.2022.03.017_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10126","key":"10.1016\/j.jfma.2022.03.017_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2022.03.017_bib7","doi-asserted-by":"crossref","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2022.03.017_bib8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.jfma.2022.03.017_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.jfma.2022.03.017_bib10","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.20.02672","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline","volume":"38","author":"Gordan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S1","key":"10.1016\/j.jfma.2022.03.017_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.31327","article-title":"Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference","volume":"73","author":"Llovet","year":"2021","journal-title":"Hepatology"},{"issue":"3_suppl","key":"10.1016\/j.jfma.2022.03.017_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","author":"Finn","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6382","key":"10.1016\/j.jfma.2022.03.017_bib13","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jfma.2022.03.017_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"10088","key":"10.1016\/j.jfma.2022.03.017_bib15","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jfma.2022.03.017_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jfma.2022.03.017_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jfma.2022.03.017_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"issue":"15_suppl","key":"10.1016\/j.jfma.2022.03.017_bib21","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2020.38.15_suppl.4508","article-title":"Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"38","author":"Kelley","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2022.03.017_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"25","key":"10.1016\/j.jfma.2022.03.017_bib24","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib25","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jfma.2022.03.017_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jfma.2022.03.017_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2326-6066.CIR-18-0605","article-title":"Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma","volume":"7","author":"Kaseb","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"6453","key":"10.1016\/j.jfma.2022.03.017_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jfma.2022.03.017_bib29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"43","key":"10.1016\/j.jfma.2022.03.017_bib30","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"15","key":"10.1016\/j.jfma.2022.03.017_bib31","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jfma.2022.03.017_bib32","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1919764117","article-title":"Combining microenvironment normalization strategies to improve cancer immunotherapy","volume":"117","author":"Mpekris","year":"2020","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib33","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","article-title":"Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2022.03.017_bib34","first-page":"1","article-title":"Pursuing efficacious systemic therapy for hepatocellular carcinoma","author":"Cheng","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from theESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2022.03.017_bib36","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jfma.2022.03.017_bib37","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2022.03.017_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3_suppl","key":"10.1016\/j.jfma.2022.03.017_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2021.39.3_suppl.269","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): long-term results from CheckMate 040","volume":"39","author":"El-Khoueiry","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3_suppl","key":"10.1016\/j.jfma.2022.03.017_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2021.39.3_suppl.313","article-title":"Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC)","volume":"39","author":"Song","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.jfma.2022.03.017_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2022.03.017_bib43","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/hep.27290","article-title":"Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial","volume":"60","author":"Kudo","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","article-title":"Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"3","author":"Kudo","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"14","key":"10.1016\/j.jfma.2022.03.017_bib45","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","article-title":"Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma","volume":"47","author":"Kudo","year":"2011","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.jfma.2022.03.017_bib46","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jfma.2022.03.017_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3_suppl","key":"10.1016\/j.jfma.2022.03.017_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JCO.2021.39.3_suppl.270","volume":"39","author":"Kudo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"10.1016\/j.jfma.2022.03.017_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000343830","article-title":"Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy","volume":"1","author":"Hsu","year":"2012","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.jfma.2022.03.017_bib50","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.24149","article-title":"Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma","volume":"53","author":"Mizukoshi","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jfma.2022.03.017_bib51","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4049\/jimmunol.178.3.1914","article-title":"Unmasking of \u03b1-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization","volume":"178","author":"Ayaru","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2019.09.023","article-title":"Role of locoregional therapies in the wake of systemic therapy","volume":"72","author":"Palmer","year":"2020","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2022.03.017_bib53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000502905","article-title":"A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-016-9771-0","article-title":"Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers","volume":"11","author":"Kimura","year":"2017","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000480208","article-title":"Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in kinki criteria stages B1 and B2","volume":"35","author":"Arizumi","year":"2017","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.jfma.2022.03.017_bib56","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/hepr.13048","article-title":"Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child\u2013Pugh grade deterioration after initial conventional transarterial chemoembolization","volume":"48","author":"Yasui","year":"2018","journal-title":"Hepatol Res"},{"issue":"8","key":"10.1016\/j.jfma.2022.03.017_bib57","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child\u2013pugh A liver function: a proof-of-concept study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.jfma.2022.03.017_bib58","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib59","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hep.31697","article-title":"Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma","volume":"74","author":"Pinato","year":"2020","journal-title":"Hepatology"},{"issue":"3_suppl","key":"10.1016\/j.jfma.2022.03.017_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2021.39.3_suppl.335","article-title":"Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)","volume":"39","author":"Yarchoan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jfma.2022.03.017_bib61","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2022.03.017_bib63","author":"Hsu"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.jfma.2022.03.017_bib65","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"suppl_4","key":"10.1016\/j.jfma.2022.03.017_bib67","first-page":"S698","article-title":"1008P IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC - annals of Oncology","volume":"31","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2022.03.017_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib69","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2022.03.017_bib70","article-title":"Early use of steroids affects immune cells and impairs immunotherapy efficacy","volume":"4","author":"Corte","year":"2019","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.jfma.2022.03.017_bib71","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"28","key":"10.1016\/j.jfma.2022.03.017_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2022.03.017_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Brief report: early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"34","key":"10.1016\/j.jfma.2022.03.017_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.jfma.2022.03.017_bib75","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jfma.2022.03.017_bib76","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2022.03.017_bib77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000512781","article-title":"Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study","volume":"10","author":"Yoo","year":"2021","journal-title":"Liver Cancer"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664622001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:48:37Z","timestamp":1760539717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664622001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0929664622001395"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2022.03.017","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitors for hepatocellular carcinoma \u2013 A game changer in treatment landscape","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2022.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}